Dr. Matthew Wilner, M.D.
What this data tells you about Dr. Wilner
Dr. Matthew Wilner is an urology physician in Dallas, TX, with 19 years in practice. Based on federal Medicare data, Dr. Wilner performed 20,520 Medicare services across 5,010 unique beneficiaries.
Between the years covered by Open Payments, Dr. Wilner received a total of $3,545 from 30 pharmaceutical and/or device companies across 90 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in urology physician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Wilner is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Testosterone injection | 10,400 | $0 | $0 |
| Urinalysis with microscopic exam | 1,835 | $3 | $6 |
| BCG treatment for bladder cancer | 1,600 | $2 | $6 |
| Office visit, established patient (30-39 min) | 1,040 | $92 | $259 |
| Blood draw (venipuncture) | 842 | $8 | $17 |
| Office visit, established patient (20-29 min) | 790 | $66 | $183 |
| PSA test (prostate cancer screening) | 620 | $18 | $37 |
| Urine culture, bacterial colony count | 316 | $8 | $16 |
| Chronic care management, first 20 min/month | 292 | $50 | $127 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 278 | $133 | $378 |
| Urine culture, bacterial identification | 247 | $8 | $16 |
| Diagnostic exam of bladder and urethra using an endoscope | 229 | $189 | $495 |
| New patient office visit (45-59 min) | 196 | $123 | $336 |
| Bladder ultrasound after voiding | 192 | $8 | $22 |
| Bacterial culture, aerobic | 148 | $8 | $16 |
| Antibiotic sensitivity test | 148 | $8 | $17 |
| Testosterone (hormone) level, total | 141 | $25 | $52 |
| Injection, garamycin, gentamicin, up to 80 mg | 115 | $2 | $6 |
| Drug injection, under skin or into muscle | 107 | $11 | $29 |
| Comprehensive metabolic blood panel | 97 | $10 | $21 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 94 | $28 | $70 |
| Simple insertion of temporary bladder tube | 86 | $48 | $126 |
| Instillation of anti-cancer drug into bladder | 80 | $70 | $179 |
| Hospital follow-up visit, low complexity | 69 | $40 | $99 |
| Chronic care management, additional 20 min/month | 66 | $38 | $96 |
| Insertion of lower leg neurostimulator electrode | 57 | $92 | $242 |
| Ultrasound scan of pelvic region through rectum | 47 | $113 | $283 |
| Initial hospital admission, moderate complexity | 43 | $102 | $261 |
| Simple bladder irrigation and/or instillation | 41 | $62 | $156 |
| Biopsy of prostate gland | 37 | $187 | $491 |
| Office visit, established patient, complex (40-54 min) | 34 | $137 | $362 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 32 | $15 | $80 |
| Basic metabolic blood panel | 31 | $8 | $17 |
| Office visit, established patient (10-19 min) | 29 | $36 | $115 |
| Imaging guidance for procedure, 60 minutes or less | 26 | $12 | $31 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 22 | $219 | $604 |
| Insertion of device into abdomen with pressure and urine flow rate study | 21 | $133 | $333 |
| Hospital follow-up visit, moderate complexity | 19 | $60 | $158 |
| New patient office visit (30-44 min) | 15 | $66 | $226 |
| Automated urinalysis | 14 | $2 | $5 |
| Electronic assessment of bladder emptying | 13 | $3 | $18 |
| Complex measurement of pressure of urine flow in bladder | 11 | $199 | $499 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Wilner is a mixed practice specialist, with above-average Medicare volume (top 4% in TX), and low-engagement industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Wilner experienced with testosterone injection?
Does Dr. Wilner receive payments from pharmaceutical companies?
How do Dr. Wilner's costs compare to other urology physicians in Dallas?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology